A New Era in Alzheimer’s Care: TDRA Welcomes the Introduction of Leqembi in Canada

The Toronto Dementia Research Alliance (TDRA) welcomes the announcement that Canada has joined the growing number of jurisdictions now offering a disease-modifying therapy for individuals living with mild cognitive impairment and early-stage Alzheimer’s disease. This represents a pivotal advancement in dementia care, marking the transition from symptomatic treatment toward interventions that can alter the underlying disease process. The availability of Leqembi in Canada has the potential to transform clinical practice, improving outcomes through earlier diagnosis, timely intervention, and coordinated care pathways.

TDRA’s integrated network of academic memory clinics and research programs is well positioned to support the responsible and equitable implementation of this therapy. By leveraging our collaborative infrastructure, shared clinical databases, and expertise in multidisciplinary dementia care, TDRA aims to ensure that patients across the province can access disease-modifying therapies in a safe, evidence-informed, and sustainable manner.

As part of this work, TDRA’s Clinical Table brings together administrative and clinical leaders across partner sites to develop coordinated, high-quality care infrastructure in Toronto and across Ontario. Through its Investigations & Treatments Working Group—which includes representatives from Baycrest, the Centre for Addiction and Mental Health (CAMH), Ontario Shores Centre for Mental Health Sciences, Sunnybrook Health Sciences Centre, University Health Network, Unity Health Toronto, and the University of Toronto—TDRA is advancing shared approaches to education, equitable access, and timely diagnosis. We thank these member sites for their ongoing collaboration, which will be critical to supporting the equitable rollout of Leqembi and future disease-modifying treatments for dementia.